Oct 12 (Reuters) - Heidelberg Pharma Ag HPHA.DE :
* NINE MONTHS EARNINGS PER SHARE 0.34 EUR VERSUS 0.39 EUR
YEAR AGO
* HDP-101 CLINICAL TRIAL IN EUROPE AND US CONTINUES WITH
ADJUSTED
PROTOCOL AND LARGER NUMBER OF STUDY SITES IN EUROPE
* FIFTH PATIENT COHORT INITIATED AT 100 ΜG/KG DOSING
* PATIENT FROM THIRD COHORT CONTINUES TO BE DOSED AND SHOWS
STABLE
DISEASE
* DIVESTMENT OF MINORITY STAKE IN EMERGENCE LEADS TO HIGHER
OTHER
INCOME AND ADDITIONAL CASH INFLOWS
* SALES AND OTHER INCOME ABOVE PLAN, OTHER FINANCIALS IN
LINE WITH
PLAN
Source text for Eikon: ID:nEQ36mkHba
Further company coverage: HPHA.DE
(Reporting by Berlin Newsroom)
((berlin.newsroom@thomsonreuters.com;))